Analyst Price Targets — BLCO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 1:27 pm | — | H.C. Wainwright | $20.00 | $17.64 | TheFly | Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright |
| February 19, 2026 12:24 pm | — | Stifel Nicolaus | $16.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $16 from $15 at Stifel |
| February 19, 2026 12:23 pm | — | Deutsche Bank | $18.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank |
| February 19, 2026 11:29 am | — | Barclays | $20.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $20 from $17 at Barclays |
| February 17, 2026 1:04 pm | — | Stifel Nicolaus | $15.00 | $17.25 | TheFly | Bausch + Lomb price target raised to $15 from $14 at Stifel |
| January 27, 2026 12:53 pm | — | RBC Capital | $21.00 | $16.87 | TheFly | Bausch + Lomb price target raised to $21 from $19 at RBC Capital |
| January 9, 2026 10:49 am | David Roman | Goldman Sachs | $19.00 | $17.30 | TheFly | Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs |
| January 5, 2026 11:20 am | Vijay Kumar | Evercore ISI | $18.00 | $16.58 | TheFly | Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI |
| December 2, 2025 11:24 am | — | Morgan Stanley | $21.00 | $16.56 | TheFly | Bausch + Lomb upgraded to Overweight at Morgan Stanley on pipeline potential |
| November 14, 2025 9:30 am | Douglas Miehm | RBC Capital | $19.00 | $15.69 | StreetInsider | Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital |
Latest News for BLCO
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care…
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 21.0% of Biodesix shares
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026. Forty-five presentations and posters will…
Shares of Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) have been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have given a buy
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLCO.
U.S. House Trading
No House trades found for BLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.